Hospital & Health Care - Bornel, Picardy, France
Recognized for the QUALITY AND EXPERTISE OF ITS TECHNOLOGIES by its partners such as L'Oréal, Galderma, and recently Almirall, SYMATESE GROUP has decided through its subsidiary SYMATESE AESTHETICS to enter the market of medical and surgical aesthetics because its new product ranges from numbers years of research REACH SAFETY AND PERFORMANCE STILL NEVER ACHIEVED.BREAST IMPLANT PROSTHESIS: The silicone processing know-how held by SYMATESE for more than 30 years according to high scientific requirements was recognized by the market leader in 2007 (J & J), to whom we have sold PEROUSE PLASTIE. Based on this expertise, we continued to optimize breast prostheses to create a new range of products that will provide more safety and well-being to patients. The products are not currently available.NEVELIA® DERMAL REGENERATION TEMPLATE is a sterile medical device consisting of a layer of collagen to promote dermal regeneration and a reinforced silicone sheet acting as a pseudo-epidermis, currently CE marked. This matrix is the result of our expertise in the field of skin, a competence notably recognized by L'Oréal, which acquired a license of our know-how in order to create its subsidiary Episkin: 1st global center for the predictive evaluation of cosmetic products. Click http://www.symatese.com/nevelia/ DERMAL FILLERS PRODUCTS: The hyaluronic acid transformation technology, which has already given birth to the brand EMERVEL®, now marketed under the name Restylane® by the market leader Galderma, a subsidiary of Nestlé Skin Health, is the subject of many improvements and will give birth to our new range for which Almirall and Symatese have entered into a global strategic collaboration in March 2017 collaboration for its development and commercialization in the Aesthetics field